Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.

Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry (2014) 2.57

A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry (2013) 1.03

Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry (2014) 0.91

A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neurosci Biobehav Rev (2016) 0.87

Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia. Psychiatry Res (2013) 0.78

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry (1994) 48.75

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA (1990) 17.70

Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis (2006) 8.23

Excess mortality of mental disorder. Br J Psychiatry (1998) 7.43

Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med (2003) 5.95

Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry (2005) 4.85

Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv (2002) 3.15

Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry (2002) 2.70

A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry (2001) 2.58

Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res (1999) 2.19

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry (2005) 2.14

Wine, liquor, beer, and mortality. Am J Epidemiol (2003) 2.01

Cardioprotective effects of light-moderate consumption of alcohol: a review of putative mechanisms. Alcohol Alcohol (2002) 2.00

Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull (2009) 1.95

Alcohol volume, drinking pattern, and cardiovascular disease morbidity and mortality: is there a U-shaped function? Am J Epidemiol (2002) 1.91

South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry (1994) 1.91

Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry (1991) 1.88

Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull (1990) 1.84

Recent victimization in women and men with severe mental illness: prevalence and correlates. J Trauma Stress (2001) 1.84

Epidemiologic review of marijuana use and cancer risk. Alcohol (2005) 1.76

Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry (1991) 1.66

Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol (2006) 1.61

Alcohol use and abuse in schizophrenia. A prospective community study. J Nerv Ment Dis (1989) 1.60

Comparisons of patients with comorbid psychiatric and substance use disorders: implications for treatment and service delivery. Am J Psychiatry (2004) 1.54

Marijuana use and mortality. Am J Public Health (1997) 1.47

Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull (1998) 1.42

Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Arch Intern Med (2004) 1.42

The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther (1999) 1.38

Medical marijuana and the law. N Engl J Med (2010) 1.37

Externally caused deaths for adults with substance use and mental disorders. J Behav Health Serv Res (2004) 1.37

Changes in alcohol intake and mortality: a longitudinal population-based study. Epidemiology (2004) 1.32

Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res (2001) 1.29

Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest (2003) 1.26

Cannabis and mortality among young men: a longitudinal study of Swedish conscripts. Scand J Soc Med (1990) 1.19

Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res (2004) 1.18

Risk of selected serious cardiac events among new users of antihistamines. Clin Ther (1996) 1.17

Assessing substance use disorder in persons with severe mental illness. New Dir Ment Health Serv (1996) 1.13

Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.11

The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11

Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther (2006) 1.11

Alcohol and illicit drugs in traumatic deaths: prevalence and association with type and severity of injuries. J Am Coll Surg (2004) 1.10

Alcohol consumption and cardiovascular disease mortality in hypertensive men. Arch Intern Med (2004) 1.05

Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry (2010) 1.00

Alcohol consumption and its contribution to the burden of coronary heart disease in middle-aged and older New Zealanders: a population-based case-control study. N Z Med J (2004) 0.99

AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol (2006) 0.99

Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci (1993) 0.99

The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull (2011) 0.97

Substance abuse-related mortality among middle-aged male VA psychiatric patients. Psychiatr Serv (2008) 0.96

Physical and mental health problems associated with the use of alcohol and drugs. Subst Use Misuse (2003) 0.95

Substance abuse and psychiatric co-morbidity as predictors of premature mortality in Swedish drug abusers: a prospective longitudinal study 1970-2006. BMC Psychiatry (2011) 0.95

Prevalence of comorbid psychiatric illness and substance misuse in primary care in England and Wales. J Epidemiol Community Health (2004) 0.94

Mortality, mental disorders and addiction: a 5-year follow-up of 82 homeless men in Stockholm. Nord J Psychiatry (2007) 0.94

Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat (2001) 0.93

Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J (2005) 0.93

Cannabis use and cognition in schizophrenia. Front Hum Neurosci (2009) 0.91

Substance use and male gender as risk factors for deaths and suicide--a 5-year follow-up study after deliberate self-harm. Soc Psychiatry Psychiatr Epidemiol (2004) 0.90

Substance use and five-year survival in Washington State mental hospitals. Adm Policy Ment Health (2004) 0.89

Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology (2009) 0.85

Moderate alcohol consumption and heart disease. Health Rep (2002) 0.84

Medical marijuana: informational resources for family physicians. Am Fam Physician (2009) 0.78

[Estimating mortality attributed to illegal drug use in Spain]. Med Clin (Barc) (2004) 0.77

Histories of substance abuse in patients with postpsychotic depressions. Compr Psychiatry (1989) 0.77

Risky use of alcohol, drugs and cigarettes in a psychosis unit: a 1 1/2 year follow-up of stability and changes after initial screening. BMC Psychiatry (2007) 0.76

Swiss debate whether to legalise cannabis. Alcohol and tobacco pose far greater danger, say advocates of cannabis legalisation. Lancet (2003) 0.76

Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull (2009) 4.69

A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. Nat Biotechnol (2006) 3.68

SLIM: an alternative Web interface for MEDLINE/PubMed searches - a preliminary study. BMC Med Inform Decis Mak (2005) 3.24

Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature (2004) 3.05

Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med (2006) 2.92

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89

Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: Results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation (2002) 2.32

Intact attentional control of working memory encoding in schizophrenia. J Abnorm Psychol (2006) 2.28

Morphometric assessment of the heteromodal association cortex in schizophrenia. Am J Psychiatry (2004) 2.27

Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry (2007) 2.26

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal (2012) 2.24

Subintimal angioplasty for below-the-ankle arterial occlusions in diabetic patients with chronic critical limb ischemia. J Endovasc Ther (2009) 2.22

Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons. Neuron (2003) 2.16

Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16

Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med (2003) 2.15

Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell (2002) 2.13

Depressive symptoms and heart rate variability in postmenopausal women. Arch Intern Med (2005) 2.08

Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics (2010) 2.04

Improvement in psychotic symptoms after a gluten-free diet in a boy with complex autoimmune illness. Am J Psychiatry (2015) 2.01

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99

A Doppler transient model based on the laplace wavelet and spectrum correlation assessment for locomotive bearing fault diagnosis. Sensors (Basel) (2013) 1.97

Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull (2009) 1.95

Delay discounting in schizophrenia. Cogn Neuropsychiatry (2007) 1.94

Obesity development during adolescence in a biracial cohort: the NHLBI Growth and Health Study. Pediatrics (2002) 1.92

Anticipatory vs. consummatory pleasure: what is the nature of hedonic deficits in schizophrenia? Psychiatry Res (2011) 1.91

Fiber density index correlates with reduced fractional anisotropy in white matter of patients with glioblastoma. AJNR Am J Neuroradiol (2005) 1.90

Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci U S A (2007) 1.80

Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet (2012) 1.78

Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry (2008) 1.78

Subcortical origins of human and monkey neocortical interneurons. Nat Neurosci (2013) 1.78

askMEDLINE: a free-text, natural language query tool for MEDLINE/PubMed. BMC Med Inform Decis Mak (2005) 1.77

Catalase overexpression prevents hypertension and tubular apoptosis in angiotensinogen transgenic mice. Kidney Int (2010) 1.75

Control of synaptic strength, a novel function of Akt. Neuron (2003) 1.73

Arabidopsis ASA1 is important for jasmonate-mediated regulation of auxin biosynthesis and transport during lateral root formation. Plant Cell (2009) 1.71

Mitochondrial localization and function of heme oxygenase-1 in cigarette smoke-induced cell death. Am J Respir Cell Mol Biol (2006) 1.69

Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol (2005) 1.67

Identification and characterization of neuroblasts in the subventricular zone and rostral migratory stream of the adult human brain. Cell Res (2011) 1.67

Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol (2004) 1.65

Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet (2012) 1.64

Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality. Am Heart J (2006) 1.62

Modulation of D2R-NR2B interactions in response to cocaine. Neuron (2006) 1.62

A putative cation channel, NCA-1, and a novel protein, UNC-80, transmit neuronal activity in C. elegans. PLoS Biol (2008) 1.61

ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia. Neuron (2006) 1.61

X-ray fluorescence computed tomography (XFCT) imaging of gold nanoparticle-loaded objects using 110 kVp x-rays. Phys Med Biol (2010) 1.60

Tibiofemoral kinematics and condylar motion during the stance phase of gait. J Biomech (2009) 1.59

FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron (2008) 1.59

Tannic acid stimulates glucose transport and inhibits adipocyte differentiation in 3T3-L1 cells. J Nutr (2005) 1.58

Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes (2007) 1.57

Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry (2005) 1.57

Perilipin 5 improves hepatic lipotoxicity by inhibiting lipolysis. Hepatology (2015) 1.55

Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res (2011) 1.55

Evidence-based medicine among internal medicine residents in a community hospital program using smart phones. BMC Med Inform Decis Mak (2007) 1.54

MMSPix - A multimedia service (MMS) medical images weblog. AMIA Annu Symp Proc (2007) 1.53

Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. J Neurosci (2004) 1.51

Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res (2009) 1.50

Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol (2005) 1.49

Retrograde transdorsal-to-plantar or transplantar-to-dorsal intraluminal re-entry following unsuccessful subintimal angioplasty for below-the-ankle arterial occlusion. J Endovasc Ther (2010) 1.47

The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res (2014) 1.46

Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. J Biol Chem (2006) 1.45

Influence of E3 region on conditionally replicative adenovirus mediated cytotoxicity in hepatocellular carcinoma cells. Cancer Biol Ther (2009) 1.45

Resistance to antiplatelet drugs: what progress has been made? Expert Opin Pharmacother (2014) 1.44

Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J (2007) 1.44

Antioxidant activity of compounds from the medicinal herb Aster tataricus. Comp Biochem Physiol C Toxicol Pharmacol (2003) 1.44

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood (2012) 1.43

Expression of Ca(2+)-permeable AMPA receptor channels primes cell death in transient forebrain ischemia. Neuron (2004) 1.43

Bcl-2 enhances the formation of newborn striatal long-projection neurons in adult rat brain after a transient ischemic stroke. Neurosci Bull (2012) 1.42

The effect of carvedilol treatment on chronic heart failure in pediatric patients with dilated cardiomyopathy: a prospective, randomized-controlled study. Pediatr Cardiol (2012) 1.42

Rapid measuring and modelling flavour quality changes of oxidised chicken fat by electronic nose profiles through the partial least squares regression analysis. Food Chem (2013) 1.40

Postoperative cognitive deficits and neuroinflammation in the hippocampus triggered by surgical trauma are exacerbated in aged rats. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.40

Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response. Cancer Biol Ther (2007) 1.40

Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis (2010) 1.40

Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone. Cardiovasc Ther (2009) 1.40

Identification of cotton microRNAs and their targets. Gene (2007) 1.40

The role of hair follicle nestin-expressing stem cells during whisker sensory-nerve growth in long-term 3D culture. J Cell Biochem (2013) 1.40

Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry (2007) 1.39

Synthesis and DNA cleavage activity of artificial receptor 1,4,7-triazacyclononane containing guanidinoethyl and hydroxyethyl side arms. J Org Chem (2007) 1.39

Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend (2010) 1.39

QR code for medical information uses. AMIA Annu Symp Proc (2008) 1.39

Carbon monoxide protects against liver failure through nitric oxide-induced heme oxygenase 1. J Exp Med (2003) 1.39

Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology (2004) 1.39

Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. Schizophr Bull (2009) 1.39

Fluoxetine augmentation of haloperidol in chronic schizophrenia. J Clin Psychopharmacol (2003) 1.37

Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37

Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res (2011) 1.36

Bisphenol S in urine from the United States and seven Asian countries: occurrence and human exposures. Environ Sci Technol (2012) 1.36

Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am J Transplant (2005) 1.36

Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry (2002) 1.36

Small C-terminal domain phosphatases dephosphorylate the regulatory linker regions of Smad2 and Smad3 to enhance transforming growth factor-beta signaling. J Biol Chem (2006) 1.35

Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance. BMC Genomics (2003) 1.35